Edgewise Therapeutics Inc (EWTX)

$16.37

-0.12

(-0.73%)

Market is closed - opens 7 PM, 15 Apr 2024

Performance

  • $15.79
    $16.48
    $16.37
    downward going graph

    3.54%

    Downside

    Day's Volatility :4.19%

    Upside

    0.67%

    downward going graph
  • $5.12
    $20.69
    $16.37
    downward going graph

    68.72%

    Downside

    52 Weeks Volatility :75.25%

    Upside

    20.88%

    downward going graph

Returns

PeriodEdgewise Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
74.52%
-1.1%
0.0%
6 Months
136.56%
6.7%
0.0%
1 Year
150.69%
3.2%
-0.7%
3 Years
-42.72%
15.2%
-21.6%

Highlights

Market Capitalization
1.5B
Book Value
$4.53
Earnings Per Share (EPS)
-1.57
Wall Street Target Price
30.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-20.22%
Return On Equity TTM
-30.1%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-112.8M
Diluted Eps TTM
-1.57
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.72
EPS Estimate Next Year
-2.05
EPS Estimate Current Quarter
-0.43
EPS Estimate Next Quarter
-0.45

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Edgewise Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 86.32%

Current $16.37
Target $30.50

Technicals Summary

Sell

Neutral

Buy

Edgewise Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Edgewise Therapeutics Inc
Edgewise Therapeutics Inc
-3.25%
136.56%
150.69%
-42.72%
-42.72%
Moderna, Inc.
Moderna, Inc.
1.24%
14.36%
-26.97%
-34.23%
306.89%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.2%
7.24%
10.36%
82.9%
140.93%
Novo Nordisk A/s
Novo Nordisk A/s
-5.94%
23.09%
45.57%
248.23%
394.48%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.73%
6.03%
21.0%
79.35%
117.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Edgewise Therapeutics Inc
Edgewise Therapeutics Inc
3.7
NA
NA
-1.72
-0.3
-0.2
NA
4.53
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.28
26.28
1.51
44.87
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.38
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.64
28.64
0.54
16.78
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Edgewise Therapeutics Inc
Edgewise Therapeutics Inc
Buy
$1.5B
-42.72%
3.7
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.0B
306.89%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$100.2B
140.93%
26.28
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$565.1B
394.48%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.8B
117.3%
28.64
36.68%

Institutional Holdings

  • Orbimed Advisors, LLC

    15.65%
  • FMR Inc

    6.97%
  • Viking Global Investors LP

    6.61%
  • Novo A/S

    6.52%
  • Deerfield Management Co

    4.22%
  • EcoR1 Capital, LLC

    3.75%

Company Information

edgewise therapeutics is a biotechnology company focused on developing novel therapies for diseases involving skeletal muscle. the company is headquartered in boulder, co and received its series a financing from orbimed.

Organization
Edgewise Therapeutics Inc
Employees
88
CEO
Dr. Peter A. Thompson FACP, M.D.
Industry
Healthcare

FAQs